Literature DB >> 21676603

Toxicity of hypofractionated accelerated radiotherapy concurrent with chemotherapy for non-small cell carcinoma of the lung.

R Carruthers, N O'Rourke, N Mohammed, J Hicks, I Brisbane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21676603     DOI： 10.1016/j.clon.2011.05.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  3 in total

1.  Excessive esophageal toxicity in patients with locally advanced non-small cell lung cancer treated with concurrent hypofractionated chemoradiotherapy and 3-weekly platinum doublet chemotherapy.

Authors:  Noëlle van der Voort van Zyp; Masoma Hashimzadah; Erik Kouwenhoven; Carmen Liskamp; Christa Gadellaa-van Hooijdonk; Ellen Pouw; Jose Belderbos; Klaartje Maas; Paul van de Vaart; Mirjam Mast
Journal:  Clin Transl Radiat Oncol       Date:  2022-07-07

2.  Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.

Authors:  Qiang Lin; Yue-E Liu; Xiao-Cang Ren; Na Wang; Xue-Ji Chen; Dong-Ying Wang; Jie Zong; Yu Peng; Zhi-Jun Guo; Jing Hu
Journal:  Radiat Oncol       Date:  2013-08-17       Impact factor: 3.481

3.  High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.

Authors:  Yue-E Liu; Qiang Lin; Fan-Jie Meng; Xue-Ji Chen; Xiao-Cang Ren; Bin Cao; Na Wang; Jie Zong; Yu Peng; Ya-Jun Ku; Yan Chen
Journal:  Radiat Oncol       Date:  2013-08-11       Impact factor: 3.481
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.